selected scholarly activity
-
chapters
- Apps for mental health. 395-433. 2022
- Recognizing Posttraumatic Stress Disorder in Primary Care. 131-156. 2021
- Pharmacotherapy for Adolescent Social Phobia. 301-322. 2015
- Serotonin reuptake and receptor blockers. 26-47. 2012
- Commentaries. 163-170. 2011
- Pharmacotherapy for Social Anxiety Disorder and Specific Phobia 2008
- Antiepileptic drugs in the treatment of anxiety disorders: Role in therapy. 207-249. 2008
-
conferences
- Lisdexamfetamine dimesylate in adult ADHD with anxiety disorder and depression comorbidity: A 17-week cross-over study. European Neuropsychopharmacology. S433-S433. 2019
- HOARDING IN USERS OF ONLINE CLASSIFIED ADVERTSEMENTS. European Neuropsychopharmacology. 763-763. 2018
- Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder and Depression Comorbidity: Results From a Clinical Trial. Neuropsychopharmacology. S342-S343. 2017
- Pokémon Go: is it a potential tool for mental health?. European Neuropsychopharmacology. S1125-S1125. 2017
- Prevalence of anxiety and depressive symptoms in a Canadian medical cannabis use cohort. European Neuropsychopharmacology. S1002-S1003. 2017
- Adult ADHD With Anxiety Disorder and Depression Comorbidity in a Clinical Trial Cohort. Neuropsychopharmacology. S486-S487. 2016
- Hoarding in users of online classified advertisements. European Neuropsychopharmacology. S622-S623. 2016
- Internet addiction or psychopathology in disguise? Results from a survey of college-aged internet users. European Neuropsychopharmacology. S700-S701. 2016
- Hoarding Behaviours among Users of Online Classified Advertisements. Neuropsychopharmacology. S457-S458. 2015
- P.6.e.002 Problematic internet use in the general population: results from an internet-based survey. European Neuropsychopharmacology. S627-S627. 2015
- The Use of Augmentation Strategies in Treatment Resistant Anxiety Disorders: A Systematic Review and Meta-Analysis. Neuropsychopharmacology. S350-S351. 2014
- P.4.a.007 Internet use for social communication in adolescents with social anxiety disorder. European Neuropsychopharmacology. S580-S580. 2014
- P.4.c.001 The use of augmentation strategies in treatment resistant anxiety disorders: a meta-analysis and systematic review. European Neuropsychopharmacology. S605-S606. 2014
- Augmentation strategies in treatment resistant anxiety disorders: Meta-analysis and systematic review. International Journal of Neuropsychopharmacology. 130-130. 2014
- Technology-based communication in individuals with social phobia. International Journal of Neuropsychopharmacology. 130-131. 2014
- Perceptions of Obsessive Compulsive Disorder and Potential Impact on Treatment Outcome. Neuropsychopharmacology. S529-S530. 2013
- P.4.e.007 Perceptions of obsessive compulsive disorder and the impact on treatment outcomes. European Neuropsychopharmacology. S528-S528. 2013
- P.4.e.008 The use of technology-based communication and the impact on the social functioning of individuals with and without social phobia. European Neuropsychopharmacology. S529-S529. 2013
- A Case Series of N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorders. Journal of Obsessive-Compulsive and Related Disorders. 230-231. 2013
- P.4.a.010 Adult attention deficit hyperactivity disorder and anxiety disorder comorbidity: prevalence in a clinical sample. European Neuropsychopharmacology. S362-S363. 2012
- P.4.e.007 Internet screening for anxiety disorders and effects on treatment-seeking three months later. European Neuropsychopharmacology. S376-S377. 2012
- Internet screening for anxiety disorders : Effects on treatment-seeking behaviour in a 3-month follow-up study. International Journal of Neuropsychopharmacology. 95-95. 2012
- Prevalence of adult attention deficit hyperactivity disorder in anxiety disorders sample. International Journal of Neuropsychopharmacology. 223-224. 2012
- P.4.b.005 Panic attacks and generalised anxiety disorder. European Neuropsychopharmacology. S534-S535. 2011
- P.4.b.019 Panic attacks associated with generalised anxiety disorder. European Neuropsychopharmacology. S540-S540. 2010
- P.4.a.006 Internet-based screening of anxiety disorders. European Neuropsychopharmacology. S588-S589. 2009
- P.4.f.001 The impact of changing diagnostic criteria in posttraumatic stress disorder (PTSD). European Neuropsychopharmacology. S618-S619. 2009
- P.4.a.008 A randomized placebo controlled trial of olanzapine in trichotillomania. European Neuropsychopharmacology. S452-S452. 2006
-
journal articles
- Cannabis use in Attention – Deficit/Hyperactivity Disorder (ADHD): A scoping review. Journal of Psychiatric Research. 157:239-256. 2023
- Problematic video-streaming: a short review. Current Opinion in Behavioral Sciences. 48:101232-101232. 2022
- Treatments for child and adolescent attention deficit hyperactivity disorder in low and middle-income countries: A narrative review. Asian Journal of Psychiatry. 76:103232-103232. 2022
- Mental health during the first wave of COVID-19 in Canada, the USA, Brazil and Italy. International Journal of Psychiatry in Clinical Practice. 26:148-156. 2022
- Obsessive-compulsive disorder during the COVID-19 pandemic. Journal of Psychiatric Research. 149:114-123. 2022
- Anxiety, depression and stress during the COVID-19 pandemic: Results from a cross-sectional survey. Journal of Psychiatric Research. 137:96-103. 2021
- Binge eating disorder hidden behind a wall of anxiety disorders. Journal of Psychiatry & Neuroscience. 46:E208-E209. 2021
- The gut microbiome and inflammation in obsessive‐compulsive disorder patients compared to age‐ and sex‐matched controls: a pilot study. Acta Psychiatrica Scandinavica. 142:337-347. 2020
- The role of cannabis in treating anxiety. Current Opinion in Psychiatry. 33:1-7. 2020
- Higher prevalence of irritable bowel syndrome and greater gastrointestinal symptoms in obsessive-compulsive disorder. Journal of Psychiatric Research. 118:1-6. 2019
- The gut microbiome in psychiatry: A primer for clinicians. Depression and Anxiety. 36:1004-1025. 2019
- Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users. Journal of Psychiatric Research. 111:134-139. 2019
- Prevalence of hoarding behaviours and excessive acquisition in users of online classified advertisements. Psychiatry Research. 270:194-197. 2018
- The Treatment of Refractory Generalized Anxiety Disorder. Current Treatment Options in Psychiatry. 4:404-417. 2017
- An Update on the Relationship Between the Gut Microbiome and Obsessive-Compulsive Disorder. Psychiatric Annals. 47:542-551. 2017
- Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?. Depression and Anxiety. 34:1006-1017. 2017
- There is an app for that! The current state of mobile applications (apps) for DSM-5 obsessive-compulsive disorder, posttraumatic stress disorder, anxiety and mood disorders. Depression and Anxiety. 34:526-539. 2017
- Refractory social anxiety disorder. Journal of Psychiatry & Neuroscience. 42:E1-E2. 2017
- The use of waitlists as control conditions in anxiety disorders research. Journal of Psychiatric Research. 83:112-120. 2016
- AUGMENTATION STRATEGIES FOR TREATMENT-RESISTANT ANXIETY DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Depression and Anxiety. 33:728-736. 2016
- Internet screening for anxiety disorders: Treatment-seeking outcomes in a three-month follow-up study. Psychiatry Research. 230:689-694. 2015
- Topiramate augmentation in a patient with obsessive–compulsive disorder. Journal of Psychiatry & Neuroscience. 40:E31-E32. 2015
- DSM-5 OBSESSIVE-COMPULSIVE AND RELATED DISORDERS: CLINICAL IMPLICATIONS OF NEW CRITERIA. Depression and Anxiety. 31:487-493. 2014
- Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. Journal of Psychopharmacology. 28:596-602. 2014
- Age at Immigration to Canada and the Occurrence of Mood, Anxiety, and Substance Use Disorders. Canadian Journal of Psychiatry. 58:210-217. 2013
- N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: A case series. Journal of Obsessive-Compulsive and Related Disorders. 2:48-52. 2013
- Panic Attacks in Generalized Anxiety Disorder. Journal of Nervous and Mental Disease. 201:52-55. 2013
- The Impact of Changing Diagnostic Criteria in Posttraumatic Stress Disorder in a Canadian Epidemiologic Sample. Journal of Clinical Psychiatry. 72:1034-1041. 2011
- Adult Attention Deficit Hyperactivity Disorder in an Anxiety Disorders Population. CNS Neuroscience and Therapeutics. 17:221-226. 2011
- The Burden of Anxiety Disorders on the Family. Journal of Nervous and Mental Disease. 198:876-880. 2010
- Potential use of Internet-based screening for anxiety disorders: a pilot study. Depression and Anxiety. 27:1006-1010. 2010
- A Randomized, Double-Blind, Placebo-Controlled Trial of Olanzapine in the Treatment of Trichotillomania. Journal of Clinical Psychiatry. 71:1336-1343. 2010
- The Prevalence of Migraine Headaches in an Anxiety Disorders Clinic Sample. CNS Neuroscience and Therapeutics. 16:76-82. 2010
- Trichotillomania in youth: a retrospective case series. Depression and Anxiety. 26:661-665. 2009
- Pharmacotherapy for social anxiety disorder: an update.. Israel Journal of Psychiatry and Related Sciences. 46:53-61. 2009
- Post‐Traumatic Stress Disorder in Canada. CNS Neuroscience and Therapeutics. 14:171-181. 2008
- Symptom relapse following switch from Celexa to generic citalopram: an anxiety disorders case series. Journal of Psychopharmacology. 21:472-476. 2007
- Nefazodone in the Treatment of Generalized Social Phobia. Journal of Clinical Psychiatry. 68:288-295. 2007
- Topiramate augmentation in treatment-resistant obsessive–compulsive disorder: a retrospective, open-label case series. Depression and Anxiety. 23:1-5. 2006
- Emerging Treatments for Child and Adolescent Social Phobia: AReview. Journal of Child and Adolescent Psychopharmacology. 15:589-607. 2005
- An evaluation of paroxetine in generalised social anxiety disorder. Expert Opinion on Pharmacotherapy. 6:819-830. 2005